Barbara A Brown-Elliott
Overview
Explore the profile of Barbara A Brown-Elliott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
6431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brown-Elliott B, Wallace Jr R
Antimicrob Agents Chemother
. 2022 Oct;
66(11):e0130422.
PMID: 36255269
No abstract available.
12.
Brown-Elliott B, Wallace Jr R
Antimicrob Agents Chemother
. 2022 Aug;
66(9):e0068922.
PMID: 35943269
Nontuberculous mycobacteria (NTM) infections are increasing worldwide. Mycobacterium avium complex (MAC) and the M. abscessus species are the most commonly cultured NTM and treatment options are limited, especially for the...
13.
Jung B, Samten B, Dean K, Wallace Jr R, Brown-Elliott B, Tucker T, et al.
PLoS Pathog
. 2022 Apr;
18(4):e1010454.
PMID: 35363832
Nontuberculous mycobacteria (NTM) infection is common in patients with structural lung damage. To address how NTM infection is established and causes lung damage, we established an NTM mouse model by...
14.
Davidson R, Nick S, Kammlade S, Vasireddy S, Weakly N, Hasan N, et al.
J Clin Microbiol
. 2021 Oct;
60(1):e0154721.
PMID: 34705540
Whole-genome sequencing (WGS) has recently been used to investigate acquisition of Mycobacterium abscessus. Investigators have reached conflicting conclusions about the meaning of genetic distances for interpretation of person-to-person transmission. Existing...
15.
Davidson R, Benoit J, Kammlade S, Hasan N, Epperson L, Smith T, et al.
Sci Rep
. 2021 Jul;
11(1):15336.
PMID: 34321532
Recent studies have characterized a dominant clone (Clone 1) of Mycobacterium abscessus subspecies massiliense (M. massiliense) associated with high prevalence in cystic fibrosis (CF) patients, pulmonary outbreaks in the United...
16.
Griffith D, Thomson R, Flume P, Aksamit T, Field S, Addrizzo-Harris D, et al.
Chest
. 2021 Apr;
160(3):831-842.
PMID: 33887244
Background: In the CONVERT study, treatment with amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) met the primary end point of increased culture conversion by month 6 in...
17.
Winthrop K, Flume P, Thomson R, Mange K, Yuen D, Ciesielska M, et al.
Ann Am Thorac Soc
. 2020 Dec;
18(7):1147-1157.
PMID: 33326356
Patients with refractory complex (MAC) lung disease have limited treatment options. In the CONVERT study, amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) increased culture conversion rates versus...
18.
Brown-Elliott B, Wallace Jr R
Antimicrob Agents Chemother
. 2020 Dec;
65(3).
PMID: 33288634
Infections caused by nontuberculous mycobacteria (NTM) are increasing globally. complex (MAC) and complex are the most frequently encountered NTM, and oral treatment options are extremely limited for these pathogens, especially...
19.
Brown-Elliott B, Molina S, Fly T, Njie O, Stribley P, Stephenson D, et al.
Heliyon
. 2019 Nov;
5(10):e02684.
PMID: 31687514
This single center study assessed the performance of a novel solid rapidly-growing mycobacteria (RGM) medium for the recovery of nontuberculous mycobacteria (NTM), especially complex, in patients with underlying bronchiectasis. A...
20.
Brown-Elliott B, Woods G
J Clin Microbiol
. 2019 Jul;
57(10).
PMID: 31315954
Recommendations for first-line and second-line drug testing and organism group, specific methodologies, and reporting recommendations have been addressed by the Clinical and Laboratory Standards Institute (CLSI) and are important in...